A Medication Study for Those with Relapsing Forms of Multiple Sclerosis
Official Title
A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis.
Purpose
This study is being done to determine how effective an investigational new drug (Ublituximab) is when given to those who have multiple sclerosis and what side effects may happen. Ublituximab has not yet been approved by the United States Food and Drug Administration (FDA), and is for use in clinical trials for people with relapsing forms of multiple sclerosis. The purpose of this clinical trial is to determine what dose and effect the study drug, Ublituximab, has on Multiple Sclerosis (MS) and those who have MS.
Could this study be right for you?
- Ages 18-55
- Diagnosis of Relapsing Multiple Sclerosis
- 2 or more relapses in prior 2 years or 1 relapse in the year prior to screening
- Active disease
- Other eligibility criteria to be discussed during screening